Meningioma. Malignant neoplasm of meninges, unspecified
Conditions
Interventions
Intervention group: The patients will receive at least 3 doses of 200 mCi Lu177-dotatate with at least 6 weeks interval. For each cycle, before Lu177-dotatate infusion, anti-emetic and dexamethasone w
Sponsors
Shiraz University of Medical Sciences
Parsisotope Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Pathologically-proved case of meningioma Radiologic evidence of recurrence after at least two surgeries with no response to other standard therapies Sufficient radiotracer uptake in the Tc99m-octreotide scan Hemoglobulin (HB)>8 g/dl White blood cell count (WBC) > 2500 /mm3 platelet count>70000 /mm3 Glomerular filtration rate (GFR) > 50ml/min Consent to participate in the study Life expectancy more than 6 months
Exclusion criteria
Exclusion criteria: Pregnancy or lactation Being candidate for other therapeutic measures Development of unpredictable complications or other limiting or severe diseases Severe hematologic complications Severe renal complications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in tumor size based on MRI findings. Timepoint: Before and during 3-6 months after therapy. Method of measurement: Brain MRI.;Change in radiotracer tumoral uptake based on Tc99m-octreotide scan. Timepoint: Before and during 3-6 months after therapy. Method of measurement: Tc99m-ocreotide scan.;Hematologic toxicity. Timepoint: 4-5 weeks after each cycle. Method of measurement: Complete blood count (CBC).;Renal toxicity. Timepoint: 4-5 weeks after each cycle. Method of measurement: Measurement of creatinine by laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Ghaedian
Shiraz University of Medical Sciences
Outcome results
None listed